Lexaria Bioscience Corp.
LEXX
NASDAQ·Healthcare·Biotechnology·Mkt cap $23.4M
$14.15
▲ +14.85%
P/E
-50.96
Mkt Cap
$23.4M
52-Wk Range
$4.21–$23.25
52-Week Range
$4.21 - $23.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 9.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary DehydraTECH platform with 23 granted patents and 50 pending
- Superior bioavailability improvements (5-27x increase vs. competitors)
- Blood-brain barrier penetration capability
- In-house licensed research laboratory and manufacturing expertise
Bear Case
1 risk
- Low volatility (beta 0.3).
Growth
Stable outlook
Regulatory approvals for cannabinoid and antiviral applications
Value
Deep value opportunity - significant discount to sector peers
Momentum
Hot
+48.0% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying LEXX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 28, 2026
JUL 13, 2026
Reported EPS of -$0.08 vs -$0.06 consensus (-33.3% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-33.3%
Revenue trend · last 5Q
+107%
+107%
—
-89%
-100%
Q3 25
Q4 25
Q1 25
Q2 26
Q3 26
$125.2K
$125.2K
$0
$14.4K
$0
Margins · last 5Q
Gross
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How LEXX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.